{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"CTNNB1 (\u03b2-catenin), a transcriptional activator, is recurrently mutated in various cancers including endometrial and hepatocellular cancers.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":true,
  "lastUpdate":"03/09/2017",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[]
    },
    "description":"",
    "knownEffect":"Unknown"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"G34_I35delinsD",
    "alterationType":null,
    "consequence":null,
    "entrezGeneId":1499,
    "hgvs":null,
    "hugoSymbol":"CTNNB1",
    "id":null,
    "proteinEnd":null,
    "proteinStart":null,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":false,
  "variantSummary":"The CTNNB1 G34_I35delinsD alteration has been identified as a statistically significant hotspot and is likely to be oncogenic.",
  "vus":false
}